Figure 7

KDM4B is expressed in hypoxic regions of tumor xenografts. (a–d) KDM4B. (e–h) Pimonidazole. (i–l) PAX8. (m–p) Ki67. (q–t) IgG. (u–x) Hematoxylin and eosin (H&E). Scale bar, 100 μm. H, hypoxia; N, necrosis. (a, e, i, m, q) And (u) correspond to SKOV3ip.1 shGFP control tumor sections. (b, f, j, n, r) And (v) correspond to SKOV3ip.1 shK-2 KDM4B knockdown tumor sections. (c, g, k, o, s) And (w) correspond to OVCAR8 shGFP control tumors. (d, h, l, p, t) And (x) correspond to OVCAR8 shK-2 tumor sections. All immunohistochemical (IHC) sections were counterstained with hematoxylin to visualize cell nuclei. Images were captured at × 00X magnification. Scale bar, 200 μm. (y) Quantitative real-time PCR (qRT–PCR) measurement of KDM4 subfamily members in SKOV3ip.1 xenograft tumors, as described in the Materials and methods (shGFP, n=7; shK-1, n=7; shK-2, n=7). (z) The qRT–PCR measurement of KDM4 subfamily members in OVCAR8 xenograft tumors (shGFP, n=10; shK-1, n=9; shK-2, n=8). Data represent average fold change relative to shGFP control, after normalization to homo sapiens GAPDH. Significance was calculated by Mann–Whitney U-test relative to shGFP control (*P<0.05; #P<0.005). Note colocalization of KDM4B with pimonidazole staining near the necrotic core of the OVCAR8 shGFP biopsy (c, g).